ALTERNATIVES 
The alternatives are not to participate in this research study. In that event, the bone marrow would be 
obtained from your twin donor in the usual manner under general anesthesia and require an overnight 
stay in the hospital. 
OTHER INFORMATION 
This treatment is being undertaken for the above described fatal disease. In agreeing to participate in a 
research program you are choosing to receive therapy that is not yet available outside of research 
institutions. This therapy is based on laboratory studies and/or exchange of information with other 
research centers. Although we expect it to benefit your condition, there is no assurance that it will do 
so, and it is possible that you may have unfavorable complications which might also be fatal 
Your decision to participate in this study is voluntary. You can decide whether or not to participate in 
this study. You may decide not to participate in this study at any time, for any reason, without notice. 
However, if you withdraw after some or all of the treatment is given and before the marrow is given, 
then marrow function may not return and could result in death. You will continue to receive medical 
care even if you decide to discontinue treatment on this study. 
. There is no financial compensation for participation in this program. 
It is understood that all medical expenses relating to, or arising from, these procedures will be paid by 
you and/or your insurance company. Financial compensation is not available in the event of physical 
injury, adverse effects, or death resulting from this research project Medical care will be authorized by 
the attending physician. You and/or your insurance company will be responsible for all costs arising 
from the medical care. 
If you have questions regarding your costs, financial responsibilities, and/or medical insurance coverage 
for this activity, please contact the Supervisor of the Financial Consultation Office at 667-4307. 
In order to evaluate the results of this study, your medical records will need to be available, now and in 
the future, to other physicians and researchers associated with the research project. The National 
Institutes of Health, Food and Drug Administration, and Amgen (drug company making G-CSF) will 
also have to have access to this information. All precautions to maintain confidentiality of medical 
records and personal information will be taken. Your personal identity will not be revealed in any 
publication or results. Study records will be maintained indefinitely for the purpose of analysis and 
follow-up. 
If you have questions about the research [or related injury] please contact the attending physician of 
your twin, your attending physician in the Outpatient Department, Dr. Buckner or Dr. Bensinger at 
667-4453. 
If you have any questions about your rights as a research participant, please contact Karen Hansen in 
the Institutional Review Office of Fred Hutchinson Cancer Research Center at 206/667-4867. 
Recombinant DNA Research, Volume 16 
[375] 
